Skip to content

The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section

The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section

Status
Withdrawn
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02847013
Enrollment
0
Registered
2016-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2020-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Postcesarean Section, Postoperative

Brief summary

This present investigation aims to determine whether a transversus abdominous plane(TAP) block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section decreases post-operative pain. The hypothesis is that performance of the TAP block with liposomal bupivacaine will decrease post-operative narcotic use.

Interventions

DRUGTAP block w Liposomal bupivacaine

TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)

PROCEDURETAP block w normal saline

TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)

Sponsors

Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients \>18 years of age * Scheduled cesarean section with or without bilateral tubal ligation * Planned performance of a Pfannenstiel incision * Patients are schedule to have a cesarean section with a member of the Women's Health or Maternal and Fetal Medicine Departments at Penn State University Hershey S. Medical Center

Exclusion criteria

* History of opioid use * History of chronic pain syndrome * Use of general anesthesia during cesarean delivery * Postoperative SICU admission * Postpartum hemorrhage (defined as an Estimated Blood Loss of greater then 1,000mL upon completion of the cesarean section)

Design outcomes

Primary

MeasureTime frameDescription
Postoperative narcotic useinitial 48 hours postoperativelyPatient use of standard postoperative narcotics (percocet) will be measured.

Secondary

MeasureTime frameDescription
Subjective pain scores using 1-10 VAS systeminitial 48 hours postoperativelySubjective pain scores using 1-10 VAS system will be measured

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026